Replies to post #13679 on Aurinia Pharmaceuticals Inc (AUPH)

[Whalatane]

IMHO the trigger here is what they presented at Kidney Week

https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controlId=3605550
Quote:

CONCLUSION

In patients with severe LN, adding voclosporin to MMF and steroids results in statistically significantly higher CRR rates. This is clinically meaningful given that patients with severe disease are at higher risk of worse long-term outcomes and development of ESKD.

As noted in previous posts ...dialysis now cost $120K a yr per patient . Dialysis can not be denied regardless of insurance status .
Voc appears to slow progression to dialysis in this high risk severe LN population .

I am surprised tho by the buyout offer ...congrats to those who were expecting it

Kiwi